Mucolysin (Acetylcysteine)

Acetylcysteine supplies a free sulfhydryl group that breaks disulfide bonds within mucopolysaccharide glycoproteins. This chemical action reduces the viscosity and elasticity of mucus, making it easier for ciliary motion and cough to expel secretions from the respiratory tract.

The dosage of Mucolysin is determined by the prescribing healthcare professional based on the patient’s condition, age, and overall health. The prescriber will select the appropriate strength, frequency, and duration according to clinical guidelines.

Safety data for acetylcysteine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Mucolysin.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mucolysin’s active ingredient, acetylcysteine, is a thiol‑based mucolytic that directly cleaves disulfide bonds in mucus. Compared with agents such as carbocisteine, which modulate mucus production, acetylcysteine provides a more rapid reduction in mucus viscosity, making it useful for acute clearance needs.

Mucolysin should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, and store it away from direct sunlight to maintain stability.

Mucolysin is taken orally as directed by a healthcare professional. The tablet or liquid is swallowed with water, typically after meals, unless otherwise instructed. Proper administration ensures optimal absorption and effectiveness.

Serious adverse reactions, though rare, include severe allergic responses such as anaphylaxis, angioedema, and bronchospasm, particularly in patients with asthma. Hepatic dysfunction and hemolysis in individuals with G6PD deficiency have also been reported and require immediate medical attention.

Mucolysin is contraindicated in patients with known hypersensitivity to acetylcysteine or any of its excipients. Individuals with active bronchospasm, severe asthma, or G6PD deficiency should avoid use unless specifically advised by a physician.